Exact Sciences: Make It Stop!

If it wasn’t bad enough that Exact Sciences (EXAS) lost half it’s value on Tuesday after an unfavorable designation for its colon-cancer test, its shares have lost almost a quarter more today. It sure didn’t help that Wedbush analyst Zarak Khurshid cut his target price to $7 from $18. He explains why: With this note […]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.